drugset / Trial / NCT02041299

Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias

NCT02041299

Phase 4 Terminated 230 enrolled ApoPharma
RandomizedParallel-groupOpen-labelTreatment

Summary

This research is being done so that we can look at the safety and efficacy of deferiprone in people with sickle cell disease or other anemias. Deferiprone is a drug that removes iron from the body. We will be comparing deferiprone with deferoxamine, another drug that removes iron from the body.

Timeline

Start
2014-04-17
Primary completion
2019-04-20
Completion
2019-06-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Deferiprone Small molecule 25 mg/kg Oral
Subject Deferiprone Small molecule 33 mg/kg Oral
Comparator Deferoxamine Other / unclassified 20 mg/kg Subcutaneous
Comparator Deferoxamine Other / unclassified 40 mg/kg Subcutaneous
Comparator Deferoxamine Other / unclassified 50 mg/kg Subcutaneous